Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis
- 5 December 2020
- journal article
- research article
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 61 (14), 3432-3439
- https://doi.org/10.1080/10428194.2020.1811271
Abstract
The optimal chemotherapy-free regimens for treatment-naive CLL still remains undefined. We searched relevant published reports. Three trials with 1017 subjects were identified. In the network meta-analysis, acalabrutinib plus obinutuzumab (Aca + Obi) improved PFS than ibrutinib plus obinutuzumab (Ibu + Obi) (HR:0.43,p = .02) and venetoclax plus obinutuzumab (Ven + Obi) (HR:0.30,p < .001) as IRC assessment. Sensitivity analysis of investigator assessment also showed improved PFS with Aca + Obi than Ibu + Obi (HR:0.46,p = .04) and Ven + Obi (HR:0.34,p = .002). Among these first-line treatments (Aca + Obi, Ibu + Obi, Ven + Obi and chlorambucil plus obinutuzumab (Chl + Obi)), Aca + Obi regimen had the highest probability of 99.1% (IRC assessment) or 98.0% (investigator assessment) to reach the longest PFS. The survival advantage with Aca + Obi was not statistically significant, compared to Ibu + Obi (HR:0.51,p = .21) and Ven + Obi (HR:0.38,p = .07). No significant difference was found in AEs analysis. Our data indicated that Aca + Obi seemed to prolong the PFS than Ibu + Obi and Ven + Obi. Considering our limits, prospective clinical trials directly comparing these regimens are warranted.Keywords
Funding Information
- Science and Technology Development Program of Weifang (No. 2018YX049, No. 2018YX004)
This publication has 14 references indexed in Scilit:
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trialThe Lancet, 2020
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting ConditionsNew England Journal of Medicine, 2019
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trialThe Lancet Oncology, 2018
- Chronic lymphocytic leukaemiaThe Lancet, 2018
- Statistics EverywhereHemaSphere, 2018
- appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies)Annals Of Oncology, 2016
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting ConditionsNew England Journal of Medicine, 2014
- Evidence Synthesis for Decision Making 2Medical Decision Making, 2012
- The changing prevalence of comorbidity across the age spectrumCritical Reviews in Oncology/Hematology, 2008
- Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted TherapyJournal of Clinical Oncology, 2006